Related Experiment Video
Updated: Jun 21, 2026
Three-dimensional Confocal Analysis of Microglia/macrophage Markers of Polarization in Experimental Brain Injury
Published on: September 4, 2013
Magnetic resonance imaging assessment of macrophage accumulation in mouse brain after experimental traumatic brain
Lesley M Foley1, T Kevin Hitchens, Chien Ho
1Pittsburgh NMR Center for Biomedical Research, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA.
Abstract:
Macrophages contribute to secondary damage and repair after central nervous system (CNS) injury. Micron-sized paramagnetic iron oxide (MPIO) particles can label macrophages in situ, facilitating three-dimensional (3D) mapping of macrophage accumulation following traumatic brain injury (TBI), via ex vivo magnetic resonance microscopy (MRM) and in vivo monitoring with magnetic resonance imaging (MRI). MPIO particles were injected intravenously (iv; 4.5 mg Fe/Kg) in male C57BL/6J mice (n = 21). A controlled cortical impact (CCI) was delivered to the left parietal cortex. Five protocols were used in naive and injured mice to assess feasibility, specificity, and optimal labeling time. In vivo imaging was carried out at 4.7 Tesla (T). Brains were then excised for 3D MRM at 11.7 T. Triple-label immunofluorescence (MPIO via Dragon Green, macrophages via F480, and nuclei via 4,6-diamidino-2-phenylindole [DAPI]) of brain sections confirmed MPIO particles within macrophages. MRM of naives showed an even distribution of a small number of MPIO-labeled macrophages in the brain. MRM at 48-72 h after CCI and MPIO injection revealed MPIO-labeled macrophages accumulated in the trauma region. When MPIO particles were injected 6 days before CCI, MRM 48 h after CCI also revealed labeled cells at the injury site. In vivo studies of macrophage accumulation by MRI suggest that this approach is feasible, but requires additional optimization. We conclude that MPIO labeling and ex vivo MRM mapping of macrophage accumulation for assessment of TBI is readily accomplished. This new technique could serve as an adjunct to conventional MR approaches by defining inflammatory mechanisms and therapeutic efficacy of anti-inflammatory agents in experimental TBI.
Insights
Micron-sized iron oxide particles effectively label macrophages for 3D mapping of brain injury sites using magnetic resonance microscopy. This technique aids in understanding inflammation and therapeutic efficacy in traumatic brain injury (TBI) models.
Area of Science:
- Neuroscience
- Biomedical Imaging
- Immunology
Background:
- Macrophages play a dual role in central nervous system (CNS) injury, contributing to both damage and repair.
- Accurate tracking of macrophage accumulation is crucial for understanding traumatic brain injury (TBI) pathogenesis and evaluating treatments.
Purpose of the Study:
- To evaluate the feasibility of using micron-sized paramagnetic iron oxide (MPIO) particles for in situ macrophage labeling and 3D mapping in a mouse model of TBI.
- To assess the utility of ex vivo magnetic resonance microscopy (MRM) and in vivo magnetic resonance imaging (MRI) for visualizing MPIO-labeled macrophages.
Main Methods:
- MPIO particles were administered intravenously to mice subjected to controlled cortical impact (CCI).
- In vivo MRI and ex vivo MRM were used to visualize MPIO-labeled macrophages at different time points post-injury.
- Triple-label immunofluorescence confirmed MPIO co-localization with macrophages (F480) in brain sections.
Main Results:
- MRM successfully visualized MPIO-labeled macrophages, showing even distribution in naive brains and accumulation at the TBI site 48-72 hours post-injury.
- Labeling was effective even when MPIO particles were injected days before the TBI induction.
- In vivo MRI demonstrated feasibility for monitoring macrophage accumulation, though optimization is needed.
Conclusions:
- MPIO labeling combined with ex vivo MRM provides a robust method for mapping macrophage accumulation in experimental TBI.
- This technique can serve as an adjunct to conventional MR methods for studying inflammatory mechanisms and therapeutic efficacy in TBI.
